Ratio of Red Blood Cell Distribution Width to Albumin Level and Risk of Mortality

Importance The ratio of red blood cell distribution width (RDW) to albumin concentration (RAR) has emerged as a reliable prognostic marker for mortality in patients with various diseases. However, whether RAR is associated with mortality in the general population remains unknown. Objectives To explore whether RAR is associated with all-cause and cause-specific mortality and to elucidate their dose-response association. Design, Setting, and Participants This population-based prospective cohort study used data from participants in the 1998-2018 US National Health and Nutrition Examination Survey (NHANES) and from the UK Biobank with baseline information provided from 2006 to 2010. Included participants had complete data on serum albumin concentration, RDW, and cause of death. The NHANES data were linked to the National Death Index records through December 31, 2019. For the UK Biobank, dates and causes of death were obtained from the National Health Service Information Centre (England and Wales) and the National Health Service Central Register Scotland (Scotland) to November 30, 2022. Main Outcomes and Measures Potential associations between RAR and the risk of all-cause and cause-specific mortality were evaluated using Cox proportional hazards regression models. Restricted cubic spline regressions were applied to estimate possible nonlinear associations. Results In NHANES, 50 622 participants 18 years of age or older years were included (mean SD age, 48.6 18.7 years; 26 136 51.6% female), and their mean (SD) RAR was 3.15 (0.51). In the UK Biobank, 418 950 participants 37 years of age or older (mean SD, 56.6 8.1 years; 225 038 53.7% female) were included, and their mean RAR (SD) was 2.99 (0.31). The NHANES documented 7590 deaths over a median (IQR) follow-up of 9.4 (5.1-14.2) years, and the UK Biobank documented 36 793 deaths over a median (IQR) follow-up of 13.8 (13.0-14.5) years. According to the multivariate analysis, elevated RAR was significantly associated with greater risk of all-cause mortality (NHANES: hazard ratio HR, 1.83 95% CI, 1.76-1.90; UK Biobank: HR, 2.08 95% CI, 2.03-2.13), as well as mortality due to malignant neoplasm (NHANES: HR, 1.89 95% CI, 1.73-2.07; UK Biobank: HR, 1.93 95% CI, 1.86-2.00), heart disease (NHANES: HR, 1.88 95% CI, 1.74-2.03; UK Biobank: HR, 2.42 95% CI, 2.29-2.57), cerebrovascular disease (NHANES: HR, 1.35 95% CI, 1.07-1.69; UK Biobank: HR, 2.15 95% CI, 1.91-2.42), respiratory disease (NHANES: HR, 1.99 95% CI, 1.68-2.35; UK Biobank: HR, 2.96 95% CI, 2.78-3.15), diabetes (NHANES: HR, 1.55 95% CI, 1.27-1.90; UK Biobank: HR, 2.83 95% CI, 2.35-3.40), and other causes of mortality (NHANES: HR, 1.97 95% CI, 1.86-2.08; UK Biobank: HR, 2.40 95% CI, 2.30-2.50) in both cohorts. Additionally, a nonlinear association was observed between RAR levels and all-cause mortality in both cohorts. Conclusions and Relevance In this cohort study, a higher baseline RAR was associated with an increased risk of all-cause and cause-specific mortality in the general population. These findings suggest that RAR may be a simple, reliable, and inexpensive indicator for identifying individuals at high risk of mortality in clinical practice.